Sekisui Medical Co., Ltd.

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products BURLINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- SEKISUI Diagnostics' microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its UK site for clinical-grade drug substance manufacturing. Following appropriate licensure, this expansion will enable manufacturing capabilities for common drug types including enzymes, proteins and antibody fragment therapies, as well as plasmids and enzymes for cutting-edge gene therapy manufacture. Continue Reading Fermentation Gantry BioProduction by SEKISUI is SEKISUI Diagnostics' contract service offering as a fermentation-focused CDMO with expertise in proteins and downstream purification. Their microbial process development and production experience helps smooth technical transfer and process scale-up. The new Grade C microbial fermentation and purification suites will accommodate production scales up to 1,000L. "This investment supports the vision and mission of SEKISUI Diagnostics and the broader SEKISUI Medical Group by enabling the continued growth of our share of the biologics CDMO market," said Robert Schruender, President & CEO of SEKISUI Diagnostics. "We look forward to working with biopharma companies seeking an experienced partner at a time when demand is outstripping manufacturing capacity." Louise Digby, Vice President, Enzymes & BioProduction at SEKISUI Diagnostics added: "Over many years we have honed our technical and operational competency and expertise in enzyme production and microbial fermentation to serve our partners globally. This cGMP expansion enables us to support a broader customer base and expand our offering to existing customers." About SEKISUI Diagnostics We are part of SEKISUI Medical Group with over 40 years of experience supplying innovative medical diagnostics globally to physicians, hospitals, laboratories and alternate testing locations. Our product lines include clinical chemistry reagents, point-of-care tests, pre-analytic systems as well as enzymes, specialty biochemicals and the microbial CDMO business, BioProduction by SEKISUI. About SEKISUI Medical Group SEKISUI Medical Group is a diverse, global network consisting of a diagnostics business and pharmaceutical sciences business which spans drug development services and manufacturing, including active pharmaceutical ingredients and pharmaceutical intermediates, amino acids, as well as a wide range of enzymes for use in diagnostics, and biopharmaceutical contract manufacturing and more. SOURCE SEKISUI DIAGNOSTICS, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

DUBLIN, July 11, 2023 /PRNewswire/ -- The "Point of Care (POC) Molecular Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Point of Care (POC) Molecular Diagnostics estimated at US$3.2 Billion in the year 2022, is projected to reach a revised size of US$8.8 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. PCR-based, one of the segments analyzed in the report, is projected to record a 14.4% CAGR and reach US$5.7 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Genetic Sequencing-Based segment is readjusted to a revised 10.7% CAGR for the next 8-year period. The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 16.3% CAGR The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 12.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1 Billion by the year 2030. Select Competitors (Total 64 Featured) - Abbott Laboratories Bayer AG BioMerieux SA Bio-Rad Laboratories, Inc. Danaher Corporation F. Hoffmann-La Roche Ltd. Nova Biomedical OraSure Technologies, Inc. Qiagen Gmbh Sekisui Medical Co., Ltd. Zoetis Inc. Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Impact of COVID-19 Pandemic and Looming Global Recession 2020 Marked as a Year of Disruption & Transformation As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021 World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022 Pandemic Puts Intense Pressure on Healthcare Systems & Products Worldwide Molecular Diagnostics Receive Healthy Booster from COVID-19 Tests Total Number of COVID-19 Tests Conducted and Tests Per Million Population in Most Impacted Countries: As on September 27, 2021 Molecular Point-of-Care Tests for COVID-19 Witness Rapid Growth Molecular RT-PCR Emerges as the Frontline Technology for Testing COVID-19 Select Commercial Molecular Tests for COVID-19 CRISPR Emerges as Cutting-Edge Biotechnology in COVID-19 Diagnostic Market COVID-19 Affects Demand for Non- COVID Diagnostics Point of Care (POC) Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Molecular Diagnostics: Leveraging Molecular Technologies to Monitor Human Diseases Types of Molecular Diagnostics Tests An Introduction to Point of Care (POC) Molecular Diagnostics Molecular Testing Mechanisms Molecular Vs Non-Molecular POCT Global Market Prospects & Outlook PCR Technology Leads the MDx Market Infectious Diseases: The Largest Application Market Reagents and Kits Dominate the Molecular Diagnostics Market Developing Countries Present Strong Growth Prospects Competition Recent Market Activity 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing Faster Screening Necessitates Point-of-care Diagnostics for COVID-19 Pandemic Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %) Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %) PCR Plays a Vital Role in the Diagnosis of Infectious Diseases Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics Global Number of Deaths Caused Due to Communicable Diseases (In 000s) Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities Percentage Share Breakdown of Global Deaths Linked to Air Pollution Air Pollution Levels (PM2.5 Concentration (?g/m) for Major Countries Worldwide for 2020 Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020 Number of New Cancer Cases and Deaths (in Million) by Region for 2020 Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2020 Number of AIDS-Related Deaths (in Thousands) by Region for 2018 Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease Home HIV Testing Emerges as a Lucrative Option Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing Hepatitis B Prevalence Worldwide by Region Demand Continues to Surge for CLIA-Waived Molecular POC Tests Advancements in POC for Molecular Diagnostics to Drive Market Growth Nanotechnology Facilitates Development of for POC Molecular Diagnostics Healthcare Needs of the World's Aging Population: Potential Opportunity in Store Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030 Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023 Elderly Healthcare Expenditure as a % of GDP for 1970, 2010 and 2050 Challenges Facing POC Molecular Diagnostics Market 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, Aug. 30, 2022 /PRNewswire/ -- The "Point of Care (POC) Molecular Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Point of Care (POC) Molecular Diagnostics Market to Reach US$5.2 Billion by the Year 2026 Increasing prevalence of various cancers and infectious disease types constitutes the major factor to drive growth for the market for the market in the coming years. Other important factors to propel growth include growing awareness and acceptance of advanced therapeutic and diagnostic choices such as personalized medicine; biomarkers development; and advancement in proteomics and molecular techniques. Reimbursement reformations are also to an extent contributing towards fueling market growth. Increasing use of molecular diagnostics for home healthcare is another important growth driving factor for the market. The growing application of healthcare information technology for providing accurate diagnostics constitutes yet another factor supporting growth for molecular diagnostics market. Introduction of new diagnostics tests, primarily in the infectious disease application area is likely to keep the momentum going for molecular diagnostics over the forthcoming years. Amid the COVID-19 crisis, the global market for Point of Care (POC) Molecular Diagnostics estimated at US$3.2 Billion in the year 2022, is projected to reach a revised size of US$5.2 Billion by 2026, growing at a CAGR of 14.4% over the analysis period. The U.S. Market is Estimated at $1.3 Billion in 2022, While China is Forecast to Reach $558.7 Million by 2026 The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$1.3 Billion in the year 2022. The country currently accounts for a 39.71% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$558.7 Million in the year 2026 trailing a CAGR of 17.6% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.8% and 13.5% respectively over the analysis period. Hybridization-based Segment to Reach $612.3 Million by 2026 ISH or In Situ-Hybridization is another important molecular diagnostic technology. ISH is used for identifying bacterial infections. Cancer testing constitutes a common application for ISH. In the global Hybridization-based segment, USA, Canada, Japan, China and Europe will drive the 12.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$225.9 Million will reach a projected size of US$513 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$72.9 Million by the year 2026, while Latin America will expand at a 13.8% CAGR through the analysis period. Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing Faster Screening Necessitates Point-of-care Diagnostics for COVID-19 Pandemic Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics Infectious Diseases Remain Major Cause of Death in Under Developed Regions PCR Plays a Vital Role in the Diagnosis of Infectious Diseases Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics Global Number of Deaths Caused Due to Communicable Diseases (In 000s) Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities Percentage Share Breakdown of Global Deaths Linked to Air Pollution Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease Home HIV Testing Emerges as a Lucrative Option Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing Hepatitis B Prevalence Worldwide by Region Demand Continues to Surge for CLIA-Waived Molecular POC Tests Advancements in POC for Molecular Diagnostics to Drive Market Growth Nanotechnology Facilitates Development of for POC Molecular Diagnostics Healthcare Needs of the World's Aging Population: Potential Opportunity in Store Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics Challenges Facing POC Molecular Diagnostics Market 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION Companies Mentioned Abbott Laboratories Bayer AG BioMerieux SA Bio-Rad Laboratories, Inc. Danaher Corporation F. Hoffmann-La Roche Ltd. Nova Biomedical OraSure Technologies, Inc. Qiagen Gmbh Sekisui Medical Co., Ltd. Zoetis Inc. For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets